<DOC>
	<DOCNO>NCT02057172</DOCNO>
	<brief_summary>The purpose study determine optimal dose dos HM11260C , administer week skin , improve control blood sugar level patient early-stage type 2 diabetes mellitus ( T2DM ) .</brief_summary>
	<brief_title>Glycaemic Control Weekly LAPS-Exendin Versus Placebo Subjects Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Ages eligible study : 18 year 74 year Genders eligible study : Male Female Diagnosed T2DM Received diet exercise therapy without metformin monotherapy HbA1c level ≥ 7.0 % ≤ 10.0 % Females childbearing potential pregnant agree use reliable method birth control Written inform consent must obtain Pregnant nursing ( lactate ) woman Diagnosis type 1 diabetes mellitus Uncontrolled diabetes define FPG level &gt; 240 mg/dL A significant change body weight 3 month screen Any history GI intolerance Personal family history medullary thyroid cancer ( MTC ) genetic condition predisposes MTC Known history chronic pancreatitis A history alcohol drug abuse drug addiction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>glycaemic control</keyword>
	<keyword>HM11260C</keyword>
	<keyword>placebo</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>efficacy</keyword>
	<keyword>T2DM</keyword>
	<keyword>glycated haemoglobin ( HbA1c )</keyword>
	<keyword>glycosylated haemoglobin ( HbA1c )</keyword>
	<keyword>Glucagon-Like Peptide-1 ( GLP-1 ) agonist</keyword>
	<keyword>blood sugar level</keyword>
	<keyword>fast plasma glucose ( FPG )</keyword>
</DOC>